Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression

Figure 1

Metabolic changes according to CAR activity. (a) Rates of change in body weight by pioglitazone treatment after 12 weeks in CAR^+/+ and CAR^-/- mice. (b) Total body fat changes after 12 weeks. (c) Liver weight after 12 weeks. (d) Fasting insulin level after 12 weeks. (e) Intraperitoneal glucose tolerance test after 12 weeks. p < 0.05, CAR^−/− control versus CAR^−/− pioglitazone, p < 0.05, CAR^+/+ control versus CAR^+/+ pioglitazone. (f) Lipid profile after 12 weeks. p < 0.05. (G) Measurement of cholesterol and triglyceride in the liver.

(a)

(b)

(c)

(d)

(e)

(f)

(g)